Advanced Kidney Cancer
A guide for adults whose kidney cancer has spread, or is at risk of spreading. Treatment changed a lot after 2018, and this covers today's drug combinations, side effects, and questions to ask.
Welcome
Hearing that your kidney cancer has spread is a hard moment. The first thing most people do is search for survival numbers, and the figures that come up are usually a decade old. They do not match what your team is offering you today.
Treatment for advanced kidney cancer changed a great deal starting around 2018. Combination drugs that pair an immune therapy with a targeted pill now form the standard. People treated this way are living longer, and a smaller group is doing very well for many years.
This guide walks through what to ask, what to expect, and where decisions get made. It pairs with the Cancer Basics guide, which explains the words and the workup that go with any cancer. Read that one first if you have not yet.
How to use this guide. Read it at your own pace, and skip the parts that do not fit your situation. The list of questions in Chapter 13 is the part to bring to your next visit.
Where you are now
Advanced kidney cancer means the cancer has moved beyond the kidney. Treatment today is very different from what it was ten years ago. People are living longer as a result.
What "advanced" means
Doctors use the word advanced for kidney cancer that has grown into nearby blood vessels or lymph nodes, or has spread to other organs. The other word you will hear is metastatic, which means the cancer has reached far parts of the body. Lungs are most common. Bones, liver, brain, lymph nodes, and a few less common sites also show up.
Two paths to this point
- Found at first diagnosis. About 1 in 4 people with kidney cancer have spread when they are first found. The kidney mass and other spots show up on the same scan.
- Found later. Some people are treated for early kidney cancer and then learn years later that it has come back. Kidney cancer can come back many years out, even 10 or 20 years after surgery.
Both paths lead to the same decision about treatment that travels through the bloodstream.
What is true today, and what changed
Until about 2018, the main first-line drug was a single targeted pill. Average survival was around 2 to 2.5 years. Since then, four large studies have changed first-line treatment. The new standard pairs an immune therapy with another drug. Average survival on these combinations is now over 4 years. A smaller group does very well for many years, with some staying off treatment after a deep response.
A kidney cancer that has spread is usually not curable the way an early one is. The goal of treatment becomes controlling the cancer for as long as possible while protecting how you feel day to day. For many people that means years of stability on scans.
If you searched for kidney cancer survival before this guide, you likely found numbers from before 2018. Those figures were collected before today's drugs were in wide use, so they no longer match what your team is offering you. Ask your own team for current numbers for your situation.
How it gets diagnosed and staged
Before treatment, your team needs a full picture of where the cancer is and what type it is. This usually takes a few visits and a set of tests.
The scans
- CT of the chest, belly, and pelvis with contrast. The main scan to map the kidney mass and any spread. Used at diagnosis and for follow-up.
- MRI of the belly. Used to look at growth of cancer into the kidney's main vein or the large vein that returns blood to the heart. Also used when contrast dye is not safe.
- MRI of the brain. Done if you have any symptom that could be from a brain spot, and many teams now do one before starting some treatments.
- Bone imaging. A bone scan or a focused MRI if you have bone pain or a worrisome finding on CT.
PET scans are not the standard staging test for kidney cancer.
The tissue
A diagnosis is made by looking at tissue under a microscope. Your team may biopsy the kidney or a spot of spread. They can also use tissue from a past kidney surgery. The tissue tells them the type of kidney cancer, the grade, and whether any aggressive features are present. The most common type is clear cell.
Your report may mention sarcomatoid features, a more aggressive appearance under the microscope. On the older targeted-pill drugs it predicted a worse outlook. With immune therapy it is now one of the situations where the drugs work especially well. If that word appears in your pathology report, ask your team how it changes which combination they recommend.
The labs
You will get blood work that checks blood counts, kidney and liver numbers, calcium, and a value called LDH. Five of these labs feed a risk score that drives first-line drug choice. Chapter 3 covers it.
Stage
The full T, N, M staging system is in the Cancer Basics guide. For advanced kidney cancer the practical version is shorter. Stage III means cancer in the kidney plus nearby tissue or lymph nodes. Stage IV means cancer has reached a far organ, or has invaded distant structures. Almost all patients reading this guide are at Stage III or Stage IV. Stage on its own does not pick the drug, since that comes from your risk score and the type of cancer.
You are allowed to have it. Bring it to your next visit and mark any words you do not know, and your team will go through it with you. What the report says decides which drugs are options for you.
IMDC risk and your drug choice
In advanced kidney cancer, your risk group matters more than your stage when your team picks a treatment. Most patients have never heard of it.
What IMDC is
The IMDC risk score, from the International Metastatic renal cell carcinoma (RCC) Database Consortium, is a way of sorting patients into three groups based on six things measured at the start of treatment. It comes from a large database of people treated for advanced kidney cancer. The risk group helps your team predict how the cancer is likely to behave and which combination is the best fit for you.
The six factors
- How well you are able to do your normal day. Doctors rate this on a standard scale.
- How long since the kidney cancer was first found. Less than a year is one risk factor. More than a year is not.
- Hemoglobin below normal. Anemia.
- Calcium above normal.
- Neutrophils above normal. A type of white blood cell.
- Platelets above normal.
The three groups
Why it matters for your drug choice
The four first-line combinations all work across risk groups, but the supporting data differs between them. Two of the combinations have the strongest data in intermediate and poor risk. The other two are options across all groups. Sarcomatoid features tilt your team toward an immune-heavy combination because the response to those drugs in that setting can be very strong.
You can ask your team this at your next visit. "What is my IMDC risk group, and how does it affect the treatment you recommend?"
Two patients in the same IMDC group can have very different paths. The label tells your team where to start. Your response on the first set of scans, usually done around the 12-week mark, carries more weight than the group you started in.
The four first-line combinations
There are four standard first-line combinations for advanced clear cell kidney cancer. All four are reasonable, and none is the best choice for every patient. Your team picks based on your risk group, the pace of your disease, your other health, and your preferences.
| Combination | Trial | Risk groups | What is special about it |
|---|---|---|---|
| Pembrolizumab + axitinib | KEYNOTE-426 | All | Immune drug given by IV plus a pill twice a day. Steady response. |
| Nivolumab + cabozantinib | CheckMate 9ER | All | Immune drug by IV plus a pill once a day. The pill has activity in bone and brain spots. |
| Pembrolizumab + lenvatinib | CLEAR | All | Strongest early response rate of the four. The pill is also the most likely to need dose changes. |
| Nivolumab + ipilimumab | CheckMate 214 | Intermediate or poor risk | Two immune drugs together for four doses, then one alone. More side effects up front. Highest chance of a long, deep response that holds even after stopping. |
How your team chooses
- Your risk group. Two of the immune drugs together (the last row) is often picked for intermediate or poor risk, especially when the cancer has aggressive features.
- How fast the cancer is moving. If a fast early response matters, your team may lean toward an immune-and-pill combination.
- Your other health. Heart problems, blood pressure that is hard to control, autoimmune disease, a past organ transplant, or the use of immune-suppressing drugs all push the choice one way or another.
- What you can take. Pills every day need a reliable routine. IV visits need access to an infusion center.
- Your goals. Some people want the highest chance of stopping treatment one day. Some want the fewest day-to-day side effects.
What to ask
You can name the four combinations on your visit and ask which one your team is recommending and why. Two oncologists at different centers might pick different regimens for the same patient. All four are accepted standards of care.
About your kidney and single spots
If you came in with the kidney cancer still in place, the question of when, or whether, to remove it has changed. So has the role of small surgeries or focused radiation for one or two spots of spread.
Removing the kidney with the cancer
Doctors call this cytoreductive nephrectomy. For many years, the kidney came out first, and drug treatment came after. A large 2018 trial called CARMENA changed that for most patients. It showed that for people with intermediate or poor risk, drug treatment alone was at least as good as removing the kidney up front.
Many teams now use this general approach:
- Drug treatment first. Most patients with cancer that has clearly spread start systemic drug treatment first. The kidney comes out later only if there is a clear reason and the patient is doing well.
- Selected upfront surgery. A smaller group of patients with good day-to-day function, low-volume spread, and a large or symptom-causing kidney mass may have surgery first. This is a case-by-case call.
- Surgery for symptoms. The kidney can come out at any time to control bleeding, pain, or high calcium that is hard to manage.
Your team may recommend removing the kidney right away. It is fair to ask whether drug treatment first is also an option for you.
One or a few spots: oligometastatic disease
Some people have only one or a few spots of spread. Doctors call this oligometastatic. In that situation, your team may add a local treatment to a spot, on top of drug treatment or instead of it for a time.
- Surgery to remove the spot. Sometimes called metastasectomy. Most often used for a single lung spot that shows up years after the kidney came out.
- Stereotactic radiation. A focused, high-dose form of radiation given in only a few visits. Used for spine, bone, lung, and brain spots.
- Ablation. Heat or cold delivered through a needle to destroy a small spot, often in the lung or bone.
Long times between the first kidney surgery and the new spot, slow growth on scans, and only one or two sites all favor a good result. Ask your team if a local treatment fits your picture.
Several specialists share the work in advanced kidney cancer. A medical oncologist runs your drug treatment. A urologist or surgical oncologist handles the kidney, and a radiation oncologist handles focused radiation. Many cases get reviewed at a tumor board, where the whole team weighs in. You can ask if yours has been.
TKI side effects, what to watch
The pill side of your combination is called a tyrosine kinase inhibitor (TKI). The most common ones are axitinib, cabozantinib, and lenvatinib. They all share a family of side effects. Most are manageable with simple steps and dose changes.
What to expect, and what to do
- Tiredness. Very common. Often the side effect that drives a dose change. Plan rest. Tell your team if it is keeping you from doing what you need to do.
- High blood pressure. A class effect of TKIs. Your team will check your pressure often in the first weeks. Many people end up on a blood pressure pill. Track your numbers at home.
- Hand-foot skin reaction. Red, sore, sometimes peeling skin on the palms and soles. Daily moisturizer, soft socks, comfortable shoes, and avoiding very hot water all help. Tell your team early.
- Loose stools or mouth sores. Common. Bland foods, hydration, and over-the-counter mouth rinses help. Severe diarrhea is a same-day call.
- Low thyroid. Picked up on a routine blood test. Easily replaced with a daily pill.
- Protein in the urine. Found on routine labs. Tracked over time.
- Voice change, hair color change, liver enzyme changes. Mild and reversible.
Less common, more serious
TKIs can cause bleeding, blood clots, heart strain, slow wound healing, and rarely a tear in the gut. Pills are paused for a few days around any planned procedure. Tell your team if you have new chest pain, a swollen leg, a wound that is not healing, or severe belly pain.
Dose changes are normal
Roughly two out of three patients on a TKI need at least one dose reduction in the first six months. A lower dose you can stay on outperforms a full dose you have to stop.
Patients sometimes downplay symptoms because they worry the team will pull the drug. With accurate information your oncologist can drop the dose, add a supportive medication, or schedule a one or two week break. None of those options are available if your team thinks you are doing fine.
Immune side effects and the wallet card
Immune therapy works by taking the brakes off your immune system so it can find the cancer. It also lets the immune system attack normal organs. Most of these effects are mild, but a few are serious. Reporting new symptoms within a day or two lets your team start steroids before the damage spreads.
What organs can be affected
- Skin. Rash and itching. Often mild.
- Hormone glands. Thyroid problems are common. Pituitary or adrenal problems matter too. Many need lifelong hormone pills.
- Gut. Diarrhea or blood in the stool can mean immune colitis.
- Lungs. A new cough or trouble breathing can mean immune pneumonitis. Take this seriously.
- Liver, kidneys, joints, muscles. Picked up on labs or by symptoms.
- Heart. Rare but serious. Call about new chest pain or palpitations.
On the two-immune-drug combination, side effects come more often and earlier. Most teams watch you closely in the first few months.
Same day call versus ER
Call your team the same day. A spreading rash. Diarrhea or blood in your stool. A new cough or trouble breathing. Severe tiredness with dizziness. New joint pain. New headache or vision change. Blood pressure much higher than usual.
Chest pain. Severe trouble breathing. Severe belly pain with fever. Severe bleeding. New one-sided weakness. A bad headache with vomiting. A seizure. Any change in how clearly you can think. Severe back pain with leg weakness or new bowel or bladder changes can mean the spinal cord is being pressed.
An immune therapy wallet card tells any ER or other doctor that you are on a checkpoint inhibitor. Steroids, antibiotics, and timing all change in this group. Most cancer centers will give you one. If yours did not, ask.
Living with treatment, and palliative care
Treatment for advanced kidney cancer often runs for years. The people around you get pulled in too.
The long-haul nature of this
Most patients stay on first-line treatment for somewhere between 15 months and a few years. Treatment fatigue, the slow accumulation of low-grade side effects and visits, tends to set in by month six or nine. Tell your team about gradual changes in how you feel, not only the bad days. A small dose adjustment or a one-week break sometimes resets it.
Scanxiety
The week before a scan is anxious for most people. Doctors and patients both call this scanxiety. Most people on first-line treatment get scans every 8 to 12 weeks, so the cycle repeats. Scheduling the scan for early in the week shortens the wait. Booking a brief follow-up call within 48 hours of the result means you are not waiting days to hear it. If the anxiety is interfering with sleep, work, or your relationships, two or three sessions with a therapist who works with cancer patients usually helps.
Palliative care belongs early
Palliative care is a parallel team that handles pain, nausea, fatigue, sleep, mood, and family conversations while your oncologist handles the cancer. Multiple randomized trials in lung and other cancers show patients who see palliative care early feel better and, in some studies, live longer. A common worry is that a referral means the team is giving up. It does not. Ask for one within the first month or two of starting treatment.
Money, work, and family
These drugs are expensive, often with list prices over $15,000 a month. Most patients never pay anywhere near that. Manufacturer co-pay programs, foundation grants like the Patient Access Network, and your cancer center's oncology social worker can bring what you actually pay down a long way. Ask for a social worker referral on your first or second visit. The federal Family and Medical Leave Act protects up to 12 weeks of unpaid, job-protected time off for serious illness if your employer is covered. Your social worker can walk you through what your specific job allows.
Fertility, if it applies
Advanced kidney cancer can show up in younger adults. If you might want children, ask about sperm or egg banking before treatment starts. Raise it at your first visit.
Bone, brain, and other spots
Some sites of spread need their own plan on top of your main drug treatment. Bone and brain are the two that come up most often.
Bone spots
Kidney cancer can spread to bone. The risks are pain, fracture from a small injury, and a sudden loss of strength if a bone in the spine puts pressure on the spinal cord.
- Bone-strengthening medicine. Two options here. Zoledronic acid is given by IV. Denosumab is given by injection under the skin. Both lower the chance of fracture and pain crises. Both can lower calcium and rarely cause a jaw bone problem.
- A dental visit before starting. Get a dental check before the first dose. Treat any active dental problem first. Tell your dentist you are starting one of these drugs.
- Focused radiation for a painful spot. A short course of radiation often gives strong relief. Stereotactic radiation is used for select spine or bone spots.
- Surgery for a bone at risk of breaking. A bone with a large hole, or one already fractured, may need a metal rod or plate.
Brain spots
- Stereotactic radiosurgery. A focused, high-dose treatment that is the most common option for one to several brain spots. Often a single visit.
- Surgery. Used for a single large spot that presses inside the skull. It is also used when a spot needs tissue for diagnosis.
- Radiation to the whole brain. Used in select cases. It can affect memory and energy.
- Steroids. Used to bring down brain swelling. Steroids can blunt how immune therapy works, so the team balances the dose carefully.
- Immune therapy can help in the brain too. Many teams treat known brain spots locally before or during their drug plan.
New severe back pain with leg weakness, trouble walking, or new bowel or bladder problems can mean the spinal cord is being pressed by a tumor. This is treatable. It needs immediate steroids, an urgent MRI, and a same-day call to a neurosurgeon and radiation team. Go to the ER if you cannot reach your team.
Other sites
Kidney cancer can spread to liver, adrenal glands, pancreas, and other places. Most are watched on scans and treated with the main drug plan. Local treatment is added when a spot is big, painful, or putting an organ at risk.
If first-line stops working
Most people will see their first treatment work for a stretch and then stop holding the cancer back. Several other drug options are available when that happens.
Second-line options
What your team picks next depends on what you had first, what worked, and the side effects you had. Common options:
- Cabozantinib. A pill with activity in bone and brain spots. Often used after a first-line that did not include it.
- Lenvatinib plus everolimus. A pill combination with a different mode of action.
- Tivozanib. A pill option for later lines.
- Axitinib. Used as a single pill in later lines.
- Belzutifan. A drug from a new class. See below.
- Single-agent immune therapy. Some patients have not had immune therapy yet, or had limited exposure. Nivolumab alone can be an option.
Belzutifan: a newer class
Belzutifan is a pill that blocks a protein called HIF-2 alpha. That protein drives much of the abnormal blood vessel growth in clear cell kidney cancer. It is a different way to attack the cancer than the IO and TKI drugs.
- Where it is used. For clear cell kidney cancer that has been treated with both an immune therapy and a targeted pill, and for tumors linked to a hereditary syndrome called VHL.
- What to watch for. Anemia is the main one. Some people need iron, blood-stimulating shots, or a transfusion. Tiredness and low oxygen levels can also occur. Headache is reported.
Clinical trials at any stage
Clinical trials are open at every line of treatment, not only at the end. Many people enroll at the first or second line. Trials at a high-volume kidney cancer center can offer options that are not yet approved. Ask your team or a research coordinator what is open.
Progression is the word your team uses when scans show the cancer growing through your current treatment. Patients almost always read it as worse news than it usually is. In most cases it means switching to a different drug class. The useful question on the visit when you hear it: "What are my options now, and which one do you recommend first?"
Genes, family, and rare types
Roughly 5 to 8 percent of kidney cancers come from an inherited gene change. Your team may suggest a meeting with a genetic counselor. They base this on your age at diagnosis, your family history, or specific features of your tumor.
When to think about genetic counseling
- Younger age at diagnosis. Under 46 is a common cutoff.
- More than one tumor in your kidneys. Or tumors in both kidneys.
- A family pattern. Several relatives with kidney cancer, or a relative with a known cancer-risk gene.
- Other tumor types in you or your family. Some non-cancer tumors of the brain or spine. Tumors of the adrenal gland called pheo. Uterine fibroids in young women. Lung cysts. Or skin findings tied to a known syndrome.
- A specific tumor type. Some kidney cancer types on your pathology report are tied to inherited syndromes.
The Cancer Basics guide goes deeper into how germline (inherited) and somatic (tumor only) testing work. Both can matter for the same person.
Why germline results matter for advanced disease
A genetic answer can change three things. It can shift your treatment, since the drug belzutifan is approved for kidney tumors tied to a VHL gene change. Surveillance for other tumors that go with that gene may be added. Blood relatives may also want testing and their own surveillance program.
Rare kidney cancer types
About 75 out of 100 advanced kidney cancers are clear cell. The rest are a mix of less common types: papillary, chromophobe, collecting duct, renal medullary, and a few rare forms. Treatment for these types is less settled.
- Papillary. Cabozantinib has activity. Combinations of immune therapy and a pill are used more and more.
- Sarcomatoid features in any type. Most teams lean toward an immune-heavy plan in this group.
- Collecting duct and renal medullary. These are aggressive. Care at a high-volume center matters. Older chemotherapy regimens are sometimes used.
- Hereditary types. Some inherited kidney cancers are treated their own way. Care at a center that sees these often is reasonable.
A federal law called GINA blocks health insurance and employers from using your genetic test results against you. It does not cover life, disability, or long-term care insurance. A genetic counselor can walk you through this before you test.
Survival numbers
Most patients look up survival numbers at some point. The figures here are current, and they describe groups of patients rather than any one person.
The big shift
For decades, the 5-year survival number for advanced kidney cancer was about 1 in 8 to 1 in 7. Today, on modern combinations, that number is much higher. Five-year survival in current studies sits in a range of 1 in 5 to 1 in 2, depending on your risk group and the regimen. Average survival on first-line combinations is now over 4 years across the four main trials.
Six things to keep in mind
- Numbers describe a group. Your case has its own risk group, sites, biology, and pace. The group number is only a starting point.
- Old numbers still show up in search results. Many of the figures online are from before 2018. They no longer match current treatment.
- Ask for numbers tied to your risk group. The starting odds for a favorable-risk patient and a poor-risk patient are very different.
- Average survival is the middle of the range. Half of people live longer, and some live much longer.
- Some people do far better than the average. A small group on dual immune therapy has lived for years, some after stopping treatment, with no sign of cancer on scans.
- Your scans matter most. How your cancer responds to your first treatment is a stronger guide than the starting number.
What durable response means
Roughly 1 in 10 patients on the two-immune-drug combination has a complete response on scans, meaning the cancer is no longer measurable on CT. A subset of those patients stop treatment after a defined period and stay off it for years. This kind of long off-treatment remission was rare before the combination era. Your team will tell you if your scans are trending that way, usually by the 6-to-9-month mark.
What if you do not respond
About 1 in 5 patients does not get a response to first-line treatment. If you land in that group, the next step is usually a switch to a different drug class, and adding focused radiation or surgery to a dominant spot is sometimes part of the plan. Clinical trials are open at this stage too. Raise the topic at the visit where progression is first mentioned so the second-line plan is ready when you need it.
Questions to ask your team
Print this page or pull it up on your phone for your next visit. The questions you want to ask are hard to remember in the room.
About my cancer
- What type of kidney cancer do I have?
- Does my pathology report mention sarcomatoid features?
- What is my IMDC risk group?
- Has my case been reviewed at a tumor board?
About the first plan
- Which of the four first-line combinations are you recommending, and why?
- Should the kidney come out now, later, or not at all?
- Are there any single spots where focused radiation or surgery would help?
- Are there clinical trials that fit my situation right now?
About side effects and life
- What side effects should I watch for, and which need a same-day call?
- Can I get an immune therapy wallet card?
- Can I see a palliative care team alongside the main treatment?
- Will this affect my fertility? Should I plan for that now?
About family and money
- Should I see a genetic counselor?
- Is there a nurse navigator or social worker I can meet?
- What help is there for the cost of these drugs?
About the path ahead
- What does it look like if this plan works? If it does not?
- What is your honest sense of what is realistic for me?
- When should we talk about end-of-life planning?
Words to know
General cancer words live in the Cancer Basics guide. These are the ones used most in advanced kidney cancer care.
- Metastatic kidney cancer
- Kidney cancer that has spread to far parts of the body.
- Locally advanced
- Cancer that has grown into nearby blood vessels or tissue but has not spread far.
- Tumor thrombus
- Tumor that has grown into the kidney's main vein or the large vein that returns blood to the heart.
- IMDC risk group
- A score that sorts patients into favorable, intermediate, or poor risk based on six things at the start of treatment.
- Clear cell
- The most common type of kidney cancer, about 3 out of 4 cases.
- Sarcomatoid features
- An aggressive look on pathology. Often responds well to immune therapy.
- Systemic therapy
- Treatment that travels through the bloodstream and reaches cancer cells anywhere in the body.
- Tyrosine kinase inhibitor (TKI)
- Targeted pills that block tumor blood-vessel signals. Examples: axitinib, cabozantinib, lenvatinib.
- Immune checkpoint inhibitor
- An immune therapy that releases the brakes on the immune system. Examples: pembrolizumab, nivolumab, ipilimumab.
- IO + TKI combination
- An immune drug paired with a TKI pill. The most common first-line approach.
- Dual immune therapy
- Two immune drugs together. In advanced kidney cancer, nivolumab plus ipilimumab.
- Immune-related adverse event
- A side effect from immune therapy when the immune system attacks normal organs.
- Cytoreductive nephrectomy
- Removing the kidney with the cancer in a person who already has spread.
- Deferred nephrectomy
- Drug treatment first, surgery on the kidney later if the patient is doing well.
- Metastasectomy
- Surgery to remove one or a few spots of spread.
- Oligometastatic
- One or only a few sites of spread.
- Stereotactic radiation
- Focused, high-dose radiation in a small number of visits.
- Bone-modifying agents
- Zoledronic acid or denosumab. Lower the chance of fracture and bone pain.
- Osteonecrosis of the jaw
- A rare jaw bone problem from bone-modifying drugs.
- Belzutifan
- A pill that blocks the HIF-2 alpha protein. Used in VHL-related and advanced clear cell tumors.
- Hand-foot reaction
- Red, sore, sometimes peeling skin on the palms and soles from a TKI pill.
- Pneumonitis
- Lung inflammation from immune therapy.
- Colitis (immune)
- Colon inflammation from immune therapy.
- Myocarditis
- Heart muscle inflammation. A rare but serious immune side effect.
- Spinal cord pressure
- Emergency from a tumor pressing on the spinal cord.
- Progression
- The cancer growing while it is being treated.
- Palliative care
- Care for symptoms and quality of life alongside treatment. Not hospice.
- Hospice
- Comfort care when treatment for control is no longer being pursued.
Sources and further reading
This guide draws on current society guidelines and the major trials behind today's standard of care. The list below points to where you can read more.
- NCCN Kidney Cancer Guidelines. nccn.org
- NCCN Patient Guidelines: Kidney Cancer. nccn.org/patients
- EAU Renal Cell Carcinoma Guidelines. uroweb.org
- ASCO Metastatic Clear Cell RCC Guideline. ascopubs.org
- KEYNOTE-426 (pembrolizumab + axitinib). nejm.org
- CheckMate 9ER (nivolumab + cabozantinib). nejm.org
- CLEAR (pembrolizumab + lenvatinib). nejm.org
- CheckMate 214 (nivolumab + ipilimumab). nejm.org
- CARMENA (cytoreductive nephrectomy era trial). nejm.org
- IMDC (Heng) risk criteria. pubmed.gov
- LITESPARK-005 (belzutifan in advanced RCC). nejm.org
- LITESPARK-001 (belzutifan in VHL). nejm.org
- PAPMET (cabozantinib in papillary RCC). pubmed.gov
- ASCO Immune-Related Adverse Events Guideline. ascopubs.org
- American Cancer Society: Kidney Cancer. cancer.org
- NCI: Kidney (Renal Cell) Cancer. cancer.gov
- Kidney Cancer Association. kidneycancer.org
- Get Palliative Care: What is palliative care? getpalliativecare.org
- ClinicalTrials.gov. clinicaltrials.gov
- National Society of Genetic Counselors (find a counselor). nsgc.org
About this guide. Work through your own situation with your care team. Use this guide to prepare for that conversation, not in place of it.